Expanding the Role of the IL-17A & IL-17F inhibiting Nanobody® Sonelokimab Across Derm & Rheum Indications – Data from a Global Placebo- & Active Comparator-Controlled Phase 2 Study in Psoriatic Arthritis
Time: 12:15 pm
day: Day Two
Details:
- Explore the rapid achievement of high response levels in joints and skin across ACR and PASI thresholds, as well as composite measures such as MDA, shedding light on the dynamics of clinical response patterns
- Consistent safety results observed in the ARGO and previous sonelokimab trials, emphasising the absence of new safety signals and contributing additional insights into the safety profile of IL-17 inhibitors
- Investigate the broader impact of sonelokimab on patient-reported quality of life, and across psoriatic disease domains, examining the depth of response beyond the primary endpoint, and its significance in the context of improving the overall well-being of patients
